A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B) a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057

Trial Profile

A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B) a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2018

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; Human Genome Sciences
  • Most Recent Events

    • 20 Jun 2018 According to a GlaxoSmithKline media release, interim results (5-6 year data) were previously announced in March 2016.
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 13 Jun 2018 According to a GlaxoSmithKline media release, data will be presented at the 2018 Annual European College of Rheumatology (EULAR).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top